Revenue
2020
2021
2022
2023
2024
2025
Prime Medicine, Inc. (PRME)
Price$3.00Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0 | $0 | $0 | $5.2M |
| Research & development | $160.6M | $155.3M | $147.9M | $86.7M | $70.5M | $3.0M |
| Operating expenses | $213.0M | $205.4M | $204.8M | $116.5M | $84.5M | $6.1M |
| Operating income | −$208.3M | −$202.5M | −$204.8M | −$116.5M | −$84.5M | −$932,000 |
| Operating margin | −4,498.06% | −6,787.36% | — | — | — | −17.89% |
| EBITDA | −$201.0M | −$196.3M | −$200.1M | −$114.3M | −$83.9M | −$889,000 |
| EBITDA margin | −4,340.00% | −6,581.93% | — | — | — | −17.06% |
| Net income | −$201.1M | −$195.9M | −$198.1M | −$121.8M | −$165.4M | −$3.4M |
| Net profit margin | −4,342.44% | −6,566.61% | — | — | — | −65.45% |
| Basic EPSper basic share | -$1.35 | -$1.65 | -$2.18 | -$4.19 | -$14.19 | -$1.91 |
| Diluted EPSper diluted share | -$1.35 | -$1.65 | -$2.18 | -$4.19 | -$14.19 | -$1.91 |
Owners
Reported shareholders
≈11.20%of listed shares
Liu David R.20.24M shares · Jun 30, 2025
View holders
| Holder | % owned |
|---|---|
Liu David R. | ≈11.20%20.24M shares |
NELSEN ROBERT | ≈10.24%18.5M shares |
GILLIS STEVEN / CRANDELL KEITH / ARCH Venture Fund X, L.P. / ARCH Venture Partners X, LLC / ARCH Venture Partners X Overage, L.P. / ARCH Venture Fund X Overage, L.P. / Burow Kristina / ARCH Venture Partners X, L.P. | ≈10.23%18.49M shares |
ARCH Venture Fund XII, L.P. / ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. | ≈10.23%18.49M shares |
Alphabet Inc. | 9.16%16.56M shares |
BlackRock, Inc. | 5.31%9.6M shares |
ARK Investment Management LLC | 4.62%8.35M shares |
STATE STREET CORP | 4.19%7.58M shares |
T. Rowe Price Investment Management, Inc. | 2.90%5.24M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.50%4.52M shares |
Gottesdiener Keith Michael | ≈2.41%4.36M shares |
Balyasny Asset Management L.P. | 2.20%3.97M shares |
GOLDMAN SACHS GROUP INC | 1.90%3.43M shares |
Casdin Capital, LLC | 1.75%3.17M shares |
Woodline Partners LP | 1.66%3M shares |
UBS Group AG | 1.55%2.79M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.50%2.71M shares |
Sumitomo Mitsui Trust Group, Inc. | 1.34%2.41M shares |
Amova Asset Management Americas, Inc. | 1.33%2.41M shares |
CITADEL ADVISORS LLC | 1.14%2.05M shares |
Percentages use 180.74M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 1, 2025Form 4 | Alphabet Inc. +3TenPercentOwner | BuyCommon Stock · indirect | 1.50M | $3.30 | $4.95M | 3.26M |
| Aug 1, 2025Form 4 | NELSEN ROBERTDirector,TenPercentOwner | BuyCommon Stock · indirect | 3.03M | $3.30 | $10.00M | 6.23M |
| Aug 1, 2025Form 4 | ARCH Venture Fund XII, L.P. +2TenPercentOwner | BuyCommon Stock · indirect | 3.03M | $3.30 | $10.00M | 6.23M |
| Aug 1, 2025Form 4 | GILLIS STEVEN +7TenPercentOwner | BuyCommon Stock · indirect | 3.03M | $3.30 | $10.00M | 6.23M |
| Jun 30, 2025Form 4 · 10b5-1 | Liu David R.TenPercentOwner | BuyCommon Stock | 21.0K | $2.52 | $52.9K | 20.24M |
Community posts
Prime Medicine receives FDA clearance to test PM647 in humans
Prime Medicine ($PRME) received FDA clearance for its investigational new drug application for PM647, a prime-editing candidate for alpha-1 antitrypsin deficiency. The decision allows a first-in-human Phase 1/2 study of a single intravenous ...
